Oncology

Latest News

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com

Patient Navigation Is Nonnegotiable in Cancer Care

By Maggie L. Shaw

May 1st 2025

Experts at the Community Oncology Conference discuss innovative patient navigation programs, emphasizing technology's role and the importance of human connection in cancer care.

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

By AJMC Contributor

May 1st 2025

Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com.jpeg

NCODA Outlines New Patient-Centered Oncology Distribution Models

By Pearl Steinzor

May 1st 2025

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

June 25th 2014

Nivolumab Trial Halted Early: Promising Phase 3 Results in Advanced Melanoma

Results indicate that nivolumab is likely to prolong survival in advanced melanoma.

June 25th 2014

FDA Panel Wants More Data for Astra's Olaparib

Safety concerns over the PARP inhibitor warranted the request for additional data.

June 24th 2014

Disappointment for Advanced NSCLC Patients Expressing EGFR WT

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer (NSCLC) in patients with wild-type epidermal growth-factor receptor (EGFR) tumour status.

June 24th 2014

FDA Questions the Efficacy of Astra's PARP Inhibitor in Ovarian Cancer Treatment

The FDA staff report questioned the unusually poor performance of the control group used in the study.

June 23rd 2014

Autologous Stem Cell Transplant Can Improve Survival in MM Patients

Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.

June 23rd 2014

FDA Warns of Intoxication Following IV Docetaxal

The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.

Ira Klein, MD, MBA, FACP Discusses How Payers Can Offer More Personalized Cancer Care to Oncologists

June 20th 2014

Ira Klein, MD, MBA, FACP Discusses How Payers Can Offer More Personalized Cancer Care to Oncologists

Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, suggests that oncology practices lack a sense of economic perspective that would otherwise allow them to offer a variety of services to their patients.

June 20th 2014

Newfound Risk That Providers, Payers, and Patients Are Navigating With the Implementation of the Affordable Care Act

A panel asks: "Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?"

June 20th 2014

Anti-CD20 Antibody Improves Lenalidomide Performance in CLL

From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.

June 20th 2014

Changing the High Cost of Cancer Care: A Multi-Stakeholder Undertaking

Katie Sullivan, MA

For patients who survive cancer, annual medical costs can be nearly double those of non-cancer patients.

June 20th 2014

Need Better Representation of Women and Minorities in Trials: Democrats

Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on ClinicalTrials.gov.

June 19th 2014

Alternate Indications: Heparin Derivative in Treating Neuroblastoma?

The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.

June 19th 2014

BRCA2 Associated With Risk of Lung Cancer Among Smokers

BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.

June 18th 2014

Pfizer Steps into the CAR-T Immunotherapy Field With Cellectis Deal

Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.

June 18th 2014

Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

June 18th 2014

3D Mammograms More Powerful than 2D

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).

June 17th 2014

Personalized Mouse TumorGrafts to Evaluate Treatment Benefits

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

June 17th 2014

Low-dose Dexamethasone with Pomalidomide Significantly Improves OS in MM

Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.

June 16th 2014

Lung-MAP Study Kicked-off at Multiple Hospitals in the United States

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.

June 16th 2014

Proteomics to Confirm Treatment Benefit in NSCLC

A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.

June 16th 2014

OncoMed Halts Enrollment and Phase 1 Dosing Studies for Vantictumab and Fzd8-Fc

June 13th 2014

NICE Proposes Ipilimumab as First-Line for Advanced Melanoma

June 13th 2014

Lymphoseek Receives FDA Approval For Diagnosis of HNSCC

The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.

June 13th 2014

Sophisticated Chest Scans in Children: Increased Risk of Heart Disease

Cutting edge technology used to image young children with heart disease increases their risk of cancer.

June 12th 2014

Ventana and MedImmune to Develop a PD-L1 Assay To Aid Patient Enrollment in Immunotherapy Trials

Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

June 12th 2014

Low Cholesterol Reduces Survival in Kidney Cancer

New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.

June 11th 2014

CYRAMZA Meets Secondary Endpoints in Phase 3 REACH Trial for HCC

CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.

June 11th 2014

The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.

June 11th 2014

Improved Detection of Metastasized Prostate Cancer with a New Tracer

A study conducted at the Johns Hopkins University demonstrates improved detection of prostate cancer metastasis following the injection of 18F-DCFBC, which binds PSMA.

June 10th 2014

Rosetta Genomics and Moffitt to Develop microRNA-Based Diagnostic

The agreement will help develop Rosetta's thyroid neoplasia assay.

...

157 158 159 160 161 162 163 164 165

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions